Wireless system offers highest definition to date, according to company.
Ultrasound developer Clarius Mobile Health announced this week the launch of its new Clarius L20HD, a system designed for medical practitioners in a variety of fields.
According to company representatives, the handheld system provides ultra-high definition medical imaging for superficial applications. It can be applied in musculoskeletal services, rheumatology, podiatry, plastic and microsurgery, pediatric anesthesia, and line placement. It is designed, they said, to replace cart-based systems that are currently used to visualize shallow anatomy.
“Every medical practitioner should have access to high definition imaging to improve confidence in diagnoses and accuracy in guided procedures,” said Laurent Pelissier, Clarius chief executive officer. “We’ve miniaturized ultrasound, without compromising image quality."
The system, which has 510(k) clearance from the U.S. Food & Drug Administration, as well as the CE Mark from the European Union, offers a frequency range of 8-to-20 MHz, enabling images down to 4 cm, and it features eight octal beams and 192 elements that provide for faster frame rates.
In addition, company officials said, it is compatible with both iOS and Android systems and can deliver images that are equivalent in quality to those captured by cart-based system, according to company details. Artificial intelligence can also adjust imaging parameters based on scanning application in real time.
The system retails for $6,900 in the United States compared to the $35,000 price tag for a cart-based system.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.